The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.
Meletios A. Dimopoulos
Honoraria - Celgene; Ortho Biotech
Katja C. Weisel
Consultant or Advisory Role - Celgene; Janssen; Onyx
Honoraria - Celgene; Janssen; Onyx
Michele Cavo
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Millennium
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Millennium
Paolo Corradini
No relevant relationships to disclose
Michel Delforge
Consultant or Advisory Role - Celgene; Janssen-Cilag
Gareth J Morgan
Honoraria - Celgene
Research Funding - Celgene
Markus Hansson
No relevant relationships to disclose
Antonio Palumbo
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Enrique M. Ocio
Research Funding - Celgene
Mathew Simcock
Employment or Leadership Position - Celgene
Neil Miller
Employment or Leadership Position - Celgene
Ana Slaughter
Employment or Leadership Position - Celgene
Nicolas Leupin
Employment or Leadership Position - Celgene
Zariana G. Nikolova
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Other Remuneration - Celgene
Philippe Moreau
Consultant or Advisory Role - Celgene (I); Celgene